Fang L,Murphy AJ,Dart AM.A clinical perspective of anti-fibrotic therapies for cardiovascular disease[J].Front Pharmacol,2017,8:186.
[2]
Ashton E,Windebank E,Skiba M,et al.Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure?Mechanistic insights from the UNIVERSE study[J].Int J Cardiol,2011,146(3):404-407.
[3]
Sarma S.Use of clinically available PPAR agonists for heart failure;do the risks outweigh the potential benefits[J].Curr Mol Pharmacol,2012,5(2):255-263.
[4]
Edgley AJ,Krum H,Kelly DJ.Targeting fibrosis for the treatment of heart failure:a role for transforming growth factor-beta[J].Cardiovasc Ther,2012,30(1):e30-e40.
[5]
Liu F,Chen Y,Feng X,et al.Effects of beta-blockers on heart failure with preserved ejection fraction:a meta-analysis[J].PLoS One,2014,9(3):e90 555.
[6]
Lopez B,Gonzalez A,Beaumont J,et al.Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure[J].J Am Coll Cardiol,2007,50(9):859-867.
[7]
Lopez B,Querejeta R,Gonzalez A,et al.Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure[J].Hypertension,2009,53(2):236-242.
[8]
Holmes DJ,Savage M,Lablanche JM,et al.Results of Prevention of REStenosis with Tranilast and its Outcomes(PRESTO)trial[J].Circulation,2002,106(10):1 243-1 250.
[9]
Aubert JD,Juillerat-Jeanneret L.Endothelin-receptor antagonists beyond pulmonary arterial hypertension:cancer and fibrosis[J].J Med Chem,2016,59(18):8 168-8 188.
[10]
Swedberg K,Komajda M,Bohm M,et al.Ivabradine and outcomes in chronic heart failure(SHIFT):a randomised placebo-controlled study[J].Lancet,2010,376(9 744):875-885.
[11]
Mcmurray JJ,Adamopoulos S,Anker SD,et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association(HFA)of the ESC[J].Eur J Heart Fail,2012,14(8):803-869.
[12]
Redfield MM,Chen HH,Borlaug BA,et al.Effect of phosphodiesterase-5inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction:a randomized clinical trial[J].JAMA,2013,309(12):1 268-1 277.
[13]
Morine KJ,Paruchuri V,Qiao X,et al.Circulating multimarker profile of patients with symptomatic heart failure supports enhanced fibrotic degradation and decreased angiogenesis[J].Biomarkers,2016,21(1):91-97.
[14]
Fang L,Ellims AH,Moore XL,et al.Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy[J].J Transl Med,2015,13(1):314.
[15]
Díez J,Querejeta R,López B,et al.Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients[J].Circulation,2002,105(21):2 512-2 517.
[16]
Kawamura M,Ito H,Onuki T,et al.Candesartan decreases typeⅢprocollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation[J].J Cardiovasc Pharmacol,2010,55(5):511-517.
[17]
Kosmala W,Przewlocka-Kosmala M,Szczepanik-Osadnik H,et al.A randomized study of the beneficial effects of aldosterone antagonism on LV function,structure,and fibrosis markers in metabolic syndrome[J].JACC Cardiovasc Imaging,2011,4(12):1 239-1 249.
[18]
Group TL.Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure:a randomized,blinded-end point,active-controlled study[J].Clin Ther,2011,33(9):1 204-1 213.
[19]
Giannetta E,Isidori AM,Galea N,et al.Chronic Inhibition of cGMP phosphodiesterase 5Aimproves diabetic cardiomyopathy:a randomized,controlled clinical trial using magnetic resonance imaging with myocardial tagging[J].Circulation,2012,125(19):2 323-2 333.
[20]
Zhang ZY,Ravassa S,Yang WY,et al.Diastolic left ventricular function in relation to urinary and serum collagen biomarkers in a general population[J].PLoS One,2016,11(12):e0167 582.
[21]
Kong P,Christia P,Frangogiannis NG.The pathogenesis of cardiac fibrosis[J].Cell Mol Life Sci,2014,71(4):549-574.
[22]
Shimada YJ,Passeri JJ,Baggish AL,et al.Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy[J].JACC Heart Fail,2013,1(6):480-487.
[23]
Kosmala W,Przewlocka-Kosmala M,Szczepanik-Osadnik H,et al.Fibrosis and cardiac function in obesity:a randomised controlled trial of aldosterone blockade[J].Heart,2013,99(5):320-326.
[24]
Mak GJ,Ledwidge MT,Watson CJ,et al.Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone[J].J Am Coll Cardiol,2009,54(18):1 674-1 682.
[25]
Deswal A,Richardson P,Bozkurt B,et al.Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial(RAAMPEF)[J].J Card Fail,2011,17(8):634-642.
[26]
Abulhul E,Mcdonald K,Martos R,et al.Long-term statin therapy in patients with systolic heart failure and normal cholesterol:effects on elevated serum markers of collagen turnover,inflammation,and B-type natriuretic peptide[J].Clin Ther,2012,34(1):91-100.
[27]
Engebretsen KV,Skardal K,Bjornstad S,et al.Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16,an orally active inhibitor of ALK5[J].J Mol Cell Cardiol,2014,76:148-157.
[28]
Tardif JC,O’Meara E,Komajda M,et al.Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function:results from the SHIFT echocardiography substudy[J].Eur Heart J,2011,32(20):2 507-2 515.
